2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Adverse Events, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Research, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1525 Incidence and survival trends in B-cell acute lymphoblastic leukemia: A population-based SEER study, 2010–2023

Abhiraj Saxena, MD, Kritika Singh, BS2, Sara Sawicki, MD3, Umma Fatema4, Aayush Visaria, MD, MPH5, Xiaoyi Chen, MD, PhD6
1 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
2 Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
3 Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
4 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
5 Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
6 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Introduction

B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric hematological malignancy, but remains uncommon in adults, who experience substantially inferior survival. The introduction of targeted therapies and immunotherapies, including blinatumomab in 2014 and CD19-directed CAR-T in 2017, has transformed the treatment landscape. However, contemporary population-based data describing outcomes across demographic and molecular subgroups remain limited. We performed a population-based study to characterize incidence, molecular subtypes, and overall survival of patients with B-ALL.

Methods

Patients with B-ALL were identified using ICD-O-3 histology codes from the SEER 21 Research Plus Database, representing approximately 45.9% of the US population. Patients with missing race or age were excluded. Patients were stratified into pediatric (<15 years), adolescent and young adult (AYA; 15–39 years), and adult (≥40 years) cohorts. Racial categories included non-Hispanic White (NHW), Black (NHB), Asian American – Pacific Islander (NHAAPI), American Indian – Alaskan Native (NHAIAN), and Hispanic patients.

Age-adjusted incidence rates (per 100,000 person-years, 2000 US standard population) were calculated. Based on their year of diagnosis, patients were grouped into diagnosis periods (2010–2013, 2014–2017, and 2018–2023) corresponding to major therapeutic milestones.

Overall survival (OS) was estimated using the Kaplan–Meier method and compared with the log-rank test. Multivariable Cox proportional hazards regression was performed, adjusting for age group, race, sex, income, diagnosis period, and molecular subtype.

Results

A total of 19254 patients were identified, with 8874 pediatric, 4037 AYA, and 6343 adult patients. The age-adjusted incidence of B-ALL was 1.0 per 100,000 person-years, with the highest incidence among the pediatric population (2.2 per 100,000 person-years).

Median ages at diagnosis for pediatric, AYA, and adult patients were 4 (IQR: 2–8), 24 (19–32), and 61 (52–71) years, respectively. Molecular subtypes showed distinct age distributions, with ETV6-RUNX1 and hyperdiploid subtypes occurring more frequently in younger patients, and BCR-ABL1 and BCR-ABL1-like occurring more frequently in AYAs and adults.

Pediatric survival remained excellent across diagnosis periods. Survival outcomes improved over time for AYA and adult patients. In the AYA cohort, 3-year survival improved from 63.5% in 2010 – 2013 to 69.7% in 2014 – 2017 and 74.9% in 2018 - 2023 (p<0.001). Improvement was observed in BCR-ABL1-positive disease, with 3-year OS increasing to 80.4% in 2018 – 2023, compared with 60.0% and 75.4% in earlier periods (p=0.0068).

Among adults, median OS improved from 14 months (95% CI: 13–16) in 2010–2013 to 19 months (17–22) in 2014–2017 and 28 months (25–33) in 2018–2023. Three-year OS increased from 33.4% to 39.9% and 46.1%, respectively. Improvements were observed in high-risk molecular subtypes, including BCR-ABL1-positive and KMT2A-rearranged B-ALL.

Among adults with BCR-ABL1-positive disease, median OS increased from 25 months (95% CI: 18–34) to 38 months (23–56) and 58 months (40–NA) across diagnosis periods. Similarly, median OS among adults with KMT2A-rearranged diseases increased from 12 to 25 months. Median OS also increased across all racial subgroups over the diagnosis periods.

In multivariable Cox regression, patients diagnosed in 2014–2017 (HR 0.84, 95% CI: 0.79 – 0.90; p<0.001) and 2018–2023 (HR 0.71, 0.67 – 0.76; p<0.001) had improved survival after adjustment for demographic and molecular factors compared with 2010-2013. Favorable molecular subtypes, including ETV6-RUNX1 (HR 0.51, 0.37 – 0.70; p<0.0001) and hyperdiploidy (HR 0.50, 0.38 – 0.66; p<0.0001), were associated with improved outcomes, whereas KMT2A-rearranged disease was associated with inferior survival (HR 1.64, 1.35 – 1.98; p<0.0001). Hispanic, NHB, and NHAIAN patients demonstrated inferior survival compared with NHW patients.

Conclusion

Overall survival has substantially improved across recent therapeutic eras, with the most pronounced gains observed among AYA and adult patients, including those with BCR-ABL1-positive disease. However, advanced age and racial disparities remain associated with inferior outcomes. These findings highlight the need for improved access to contemporary therapies among older adults and underrepresented populations, as well as continued investigation into the drivers of these disparities.

 

 

 

Abhiraj Saxena, MD: No relevant conflicts of interest to declare.